MGNX

MacroGenics, Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company. It focusses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.

MacroGenics, Inc. (MGNX) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Profitability (D+). The rating has held at C+ for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
B
Factor Score 3.2 / 5.0
Profitability
D+
Factor Score 1.8 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.6
EV / EBITDA -0.2
Rev Growth YoY 378.0%
Gross Margin -0.7%
Price Return 3M -45.7%
Price Return 12M 50.7%
Catalyst Signal 0.00
Market Cap $145.9M
TTM Revenue $175.1M
Price / Sales 0.8
ROE -225.8%

Historical Factor Score Progression

Held C+ for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (3.0) B (3.2) D+ (1.8) C (2.4) C+ (2.6) C+ (2.6)
2026-11-06 B- (3.0) B (3.2) D+ (1.8) B- (3.0) C+ (2.7) C+ (2.7)
2026-10-30 B- (3.0) B (3.2) C- (1.9) B- (3.0) C+ (2.7) C+ (2.8)
2026-10-23 B- (3.0) B (3.2) C- (1.9) B- (3.1) C+ (2.6) C+ (2.8)
2026-10-16 B- (3.0) B (3.2) C- (1.9) C+ (2.8) C+ (2.6) C+ (2.7)
Page 1 of 8
…